Legislation on direct-to-consumer genetic testing in seven European countries

被引:0
作者
Pascal Borry
Rachel E van Hellemondt
Dominique Sprumont
Camilla Fittipaldi Duarte Jales
Emmanuelle Rial-Sebbag
Tade Matthias Spranger
Liam Curren
Jane Kaye
Herman Nys
Heidi Howard
机构
[1] Centre for Biomedical Ethics and Law,Department of Clinical Genetics & Department of Medical Humanities
[2] Katholieke Universiteit Leuven,Département d′épidémiologie et de santé publique
[3] VU University Medical Center,undefined
[4] and EMGO Institute for Health and Care Research,undefined
[5] Leiden University Medical Centre,undefined
[6] Institute of Health Law,undefined
[7] University of Neuchâtel,undefined
[8] Institute of Bioethics,undefined
[9] Portuguese Catholic University,undefined
[10] UMR U 1027,undefined
[11] Inserm,undefined
[12] Université de Toulouse - Université Paul Sabatier -Toulouse III,undefined
[13] Epidémiologie et analyses en santé publique: risques,undefined
[14] maladies chroniques et handicap,undefined
[15] Institute for Public Law,undefined
[16] University of Bonn,undefined
[17] HeLEX Centre for Health,undefined
[18] Law and Emerging Technologies,undefined
[19] University of Oxford,undefined
[20] Institute for BioMedical Ethics,undefined
[21] University of Basel,undefined
来源
European Journal of Human Genetics | 2012年 / 20卷
关键词
direct-to-consumer; legal; genetic testing;
D O I
暂无
中图分类号
学科分类号
摘要
An increasing number of private companies are now offering direct-to-consumer (DTC) genetic testing services. Although a lot of attention has been devoted to the regulatory framework of DTC genetic testing services in the USA, only limited information about the regulatory framework in Europe is available. We will report on the situation with regard to the national legislation on DTC genetic testing in seven European countries (Belgium, the Netherlands, Switzerland, Portugal, France, Germany, the United Kingdom). The paper will address whether these countries have legislation that specifically address the issue of DTC genetic testing or have relevant laws that is pertinent to the regulatory control of these services in their countries. The findings show that France, Germany, Portugal and Switzerland have specific legislation that defines that genetic tests can only be carried out by a medical doctor after the provision of sufficient information concerning the nature, meaning and consequences of the genetic test and after the consent of the person concerned. In the Netherlands, some DTC genetic tests could fall under legislation that provides the Minister the right to refuse to provide a license to operate if a test is scientifically unsound, not in accordance with the professional medical practice standards or if the expected benefit is not in balance with the (potential) health risks. Belgium and the United Kingdom allow the provision of DTC genetic tests.
引用
收藏
页码:715 / 721
页数:6
相关论文
共 61 条
  • [1] Ledley F(2002)A consumer charter for genomic services Nat Biotechnol 20 767-638
  • [2] Foster MW(2006)The routinisation of genomics and genetics: implications for ethical practices J Med Ethics 32 635-13
  • [3] Royal CDM(2009)Personal genome testing: do you know what you are buying? Am J Bioethics 9 11-846
  • [4] Sharp RR(2010)Predictive and diagnostic genetic testing in psychiatry Clin Lab Med 30 829-1149
  • [5] Howard HC(2008)Gene-testing firms face legal battle Nature 453 1148-182
  • [6] Borry P(2008)The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues Annu Rev Genomics Hum Genet 9 161-292
  • [7] Mitchell PB(2006)Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests Am J Med Genet C Semin Med Genet 142 284-59
  • [8] Meiser B(2009)Direct-to-consumer genome scanning services. Also for children? Nat Rev Genet 10 8-599
  • [9] Wilde A(2009)Health-related direct-to-consumer genetic testing: a review of companies′ policies with regard to genetic testing in minors Fam Cancer 9 51-594
  • [10] Wadman M(2008)A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions Am J Hum Genet 82 593-574